SCD
MCID: SCK005
MIFTS: 57

Sickle Cell Disease (SCD)

Categories: Blood diseases, Immune diseases

Aliases & Classifications for Sickle Cell Disease

MalaCards integrated aliases for Sickle Cell Disease:

Name: Sickle Cell Disease 25 26 56 44 3
Sickling Disorder Due to Hemoglobin S 26
Sickle Cell Disorders 26
Hemoglobin S Disease 26
Anemia, Sickle Cell 74
Hbs Disease 26
Scd 26

Classifications:



External Ids:

ICD10 34 D57
UMLS 74 C0002895

Summaries for Sickle Cell Disease

MedlinePlus : 44 What is sickle cell disease? Sickle cell disease (SCD) is a group of inherited red blood cell disorders. If you have SCD, there is a problem with your hemoglobin. Hemoglobin is a protein in red blood cells that carries oxygen throughout the body. With SCD, the hemoglobin forms into stiff rods within the red blood cells. This changes the shape of the red blood cells. The cells are supposed to be disc-shaped, but this changes them into a crescent, or sickle, shape. The sickle-shaped cells are not flexible and cannot change shape easily. Many of them burst apart as they move through your blood vessels. The sickle cells usually only last 10 to 20 days, instead of the normal 90 to 120 days. Your body may have trouble making enough new cells to replace the ones that you lost. Because of this, you may not have enough red blood cells. This is a condition called anemia, and it can make you feel tired. The sickle-shaped cells can also stick to vessel walls, causing a blockage that slows or stops the flow of blood. When this happens, oxygen can't reach nearby tissues. The lack of oxygen can cause attacks of sudden, severe pain, called pain crises. These attacks can occur without warning. If you get one, you might need to go to the hospital for treatment. What causes sickle cell disease? The cause of SCD is a defective gene, called a sickle cell gene. People with the disease are born with two sickle cell genes, one from each parent. If you are born with one sickle cell gene, it's called sickle cell trait. People with sickle cell trait are generally healthy, but they can pass the defective gene on to their children. Who is at risk for sickle cell disease? In the United States, most of the people with SCD are African Americans: About 1 in 13 African American babies is born with sickle cell trait About 1 in every 365 black children is born with sickle cell disease SCD also affects some people who come from Hispanic, southern European, Middle Eastern, or Asian Indian backgrounds. What are the symptoms of sickle cell disease? People with SCD start to have signs of the disease during the first year of life, usually around 5 months of age. Early symptoms of SCD may include Painful swelling of the hands and feet Fatigue or fussiness from anemia A yellowish color of the skin (jaundice) or the whites of the eyes (icterus) The effects of SCD vary from person to person and can change over time. Most of the signs and symptoms of SCD are related to complications of the disease. They may include severe pain, anemia, organ damage, and infections. How is sickle cell disease diagnosed? A blood test can show if you have SCD or sickle cell trait. All states now test newborns as part of their screening programs, so treatment can begin early. People who are thinking about having children can have the test to find out how likely it is that their children will have SCD. Doctors can also diagnose SCD before a baby is born. That test uses a sample of amniotic fluid (the liquid in the sac surrounding the baby) or tissue taken from the placenta (the organ that brings oxygen and nutrients to the baby). What are the treatments for sickle cell disease? The only cure for SCD is bone marrow or stem cell transplantation. Because these transplants are risky and can have serious side effects, they are usually only used in children with severe SCD. For the transplant to work, the bone marrow must be a close match. Usually, the best donor is a brother or sister. There are treatments that can help relieve symptoms, lessen complications, and prolong life: Antibiotics to try to prevent infections in younger children Pain relievers for acute or chronic pain Hydroxyurea, a medicine that has been shown to reduce or prevent several SCD complications. It increases the amount of fetal hemoglobin in the blood. This medicine is not right for everyone; talk to your health care provider about whether you should take it. This medicine is not safe during pregnancy. Childhood immunizations to prevent infections Blood transfusions for severe anemia. If you have had some serious complications, such as a stroke, you may have transfusions to prevent more complications. There are other treatments for specific complications. To stay as healthy as possible, make sure that you get regular medical care, live a healthy lifestyle, and avoid situations that may set off a pain crisis. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Sickle Cell Disease, also known as sickling disorder due to hemoglobin s, is related to hereditary persistence of fetal hemoglobin-sickle cell disease syndrome and acute chest syndrome, and has symptoms including angina pectoris, abdominal pain and edema. An important gene associated with Sickle Cell Disease is MIR144 (MicroRNA 144), and among its related pathways/superpathways are Factors involved in megakaryocyte development and platelet production and African trypanosomiasis. The drugs Hydroxyurea and Peginterferon alfa-2a have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and testes, and related phenotypes are Increased shRNA abundance and cardiovascular system

Genetics Home Reference : 26 Sickle cell disease is a group of disorders that affects hemoglobin, the molecule in red blood cells that delivers oxygen to cells throughout the body. People with this disorder have atypical hemoglobin molecules called hemoglobin S, which can distort red blood cells into a sickle, or crescent, shape.

Wikipedia : 77 Sickle cell disease (SCD) is a group of blood disorders typically inherited from a person''s parents.... more...

GeneReviews: NBK1377

Related Diseases for Sickle Cell Disease

Diseases related to Sickle Cell Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 424)
# Related Disease Score Top Affiliating Genes
1 hereditary persistence of fetal hemoglobin-sickle cell disease syndrome 33.3 BCL11A HBB HBG1 HBG2
2 acute chest syndrome 32.7 HBB VCAM1
3 hemoglobinopathy 31.9 EPO HBA2 HBB HBD HBG1
4 sickle cell anemia 31.8 BCL11A EPO G6PD HBA2 HBB HBG1
5 malaria 31.4 EPO G6PD HBA2 HBB SELP VCAM1
6 splenic sequestration 31.3 BCAM HBB
7 hereditary spherocytosis 30.4 G6PD HBB HBG1
8 splenomegaly 30.4 EPO HBA2
9 hemoglobin c disease 30.2 HBB HBD
10 glucosephosphate dehydrogenase deficiency 30.1 G6PD HBB HBG2
11 deficiency anemia 29.8 EPO G6PD HBA2 HBB HBG2
12 hemolytic anemia 29.7 EPO G6PD HBA2 HBB HBG2
13 arteries, anomalies of 29.6 PGF SELP VCAM1
14 alpha-thalassemia 29.5 EPO G6PD HBA2 HBB HBG1 HBG2
15 thalassemia 29.4 BCL11A EPO HBA2 HBB HBD HBG1
16 beta-thalassemia 29.1 BCL11A EPO G6PD HBA2 HBB HBD
17 sickle cell disease associated with an other hemoglobin anomaly 12.2
18 carnitine deficiency, systemic primary 11.7
19 schnyder corneal dystrophy 11.7
20 sickle beta thalassemia 11.5
21 cardiac conduction defect 11.5
22 moyamoya disease 1 11.4
23 qt interval, variation in 11.3
24 ehlers-danlos syndrome, spondylodysplastic type, 3 11.3
25 diabetes mellitus, noninsulin-dependent 11.2
26 fanconi anemia, complementation group d2 11.2
27 body mass index quantitative trait locus 11 11.2
28 lipodystrophy, congenital generalized, type 3 11.2
29 lipodystrophy, congenital generalized, type 4 11.2
30 reye syndrome 11.2
31 fanconi anemia, complementation group a 11.1
32 fetal hemoglobin quantitative trait locus 5 11.1
33 endosteal hyperostosis, autosomal dominant 11.1
34 osteomesopyknosis 11.1
35 sickle cell - hemoglobin d disease 11.1
36 superior semicircular canal dehiscence 11.0
37 subacute cerebellar degeneration 11.0
38 semicircular canal dehiscence syndrome 11.0
39 priapism 10.7
40 refractory anemia 10.6
41 pulmonary hypertension 10.6
42 hematopoietic stem cell transplantation 10.5
43 hemosiderosis 10.5
44 osteonecrosis 10.4
45 cholelithiasis 10.4
46 pain - chronic 10.4
47 asthma 10.4
48 osteomyelitis 10.4
49 avascular necrosis of femoral head, primary, 1 10.3
50 thrombosis 10.3

Graphical network of the top 20 diseases related to Sickle Cell Disease:



Diseases related to Sickle Cell Disease

Symptoms & Phenotypes for Sickle Cell Disease

UMLS symptoms related to Sickle Cell Disease:


angina pectoris, abdominal pain, edema, chest pain

GenomeRNAi Phenotypes related to Sickle Cell Disease according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance GR00327-A 8.92 EPO G6PD HBD HBG2

MGI Mouse Phenotypes related to Sickle Cell Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.23 BCAM EPO G6PD KCNN4 PGF SELP

Drugs & Therapeutics for Sickle Cell Disease

Drugs for Sickle Cell Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 412)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydroxyurea Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 127-07-1 3657
2
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
3
Ribavirin Approved Phase 4 36791-04-5 37542
4
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
5
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 57-27-2 5288826
6
Deferasirox Approved, Investigational Phase 4,Phase 2,Phase 3 201530-41-8 5493381
7
Iron Approved, Experimental Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7439-89-6, 15438-31-0 23925 27284
8
Deferoxamine Approved, Investigational Phase 4,Phase 2,Phase 3 70-51-9 2973
9
Deferiprone Approved Phase 4,Phase 2,Phase 3,Phase 1 30652-11-0 2972
10
Proguanil Approved Phase 4,Phase 1,Phase 2,Not Applicable 500-92-5 4923
11
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 6740-88-1 3821
12
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 93-14-1 3516
13
Hydromorphone Approved, Illicit Phase 4,Phase 3,Phase 2 466-99-9 5284570
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2 437-38-7 3345
15
Sodium Citrate Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 68-04-2
16
Pyrimethamine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 58-14-0 4993
17
Amodiaquine Approved, Investigational Phase 4,Phase 1,Phase 2 86-42-0 2165
18
Sulfadoxine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 2447-57-6 17134
19
Acetaminophen Approved Phase 4,Phase 2,Phase 1,Not Applicable 103-90-2 1983
20
Codeine Approved, Illicit Phase 4,Phase 1,Phase 2 76-57-3 5284371
21
Ibuprofen Approved Phase 4,Phase 2,Not Applicable 15687-27-1 3672
22
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
23
Desogestrel Approved Phase 4 54024-22-5 40973
24
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
25
Calcium Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 7440-70-2 271
26
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 50-14-6 5280793
27
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 1406-16-2
28
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 67-97-0 5280795 6221
29
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 77-92-9 311
30
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735
31
Piperaquine Experimental, Investigational Phase 4 4085-31-8 5079497
32
Dihydroartemisinin Experimental, Investigational Phase 4 71939-50-9 6918483
33 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Interferon alpha-2 Phase 4
36 interferons Phase 4
37 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
40 Interferon-alpha Phase 4
41 Narcotics Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
42 Analgesics, Opioid Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
43 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Calcium, Dietary Phase 4,Phase 2,Phase 3,Phase 1
47 Anesthetics, General Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Anesthetics, Intravenous Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Chelating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 696)
# Name Status NCT ID Phase Drugs
1 Mobile-Directly Observed Therapy on Adherence to Hydroxyurea Unknown status NCT02844673 Phase 4 Hydroxyurea
2 Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
3 Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease Completed NCT02222246 Phase 4 Hydromorphone (Standardized, weight-based dosing);Morphine Sulfate (Standardized, weight-based dosing);Hydromorphone (Patient Specific dosing);Morphine Sulfate (Patient Specific dosing)
4 Future of Spermatogenesis in Men With Sickle Cell Disease Medically Treated Completed NCT01609192 Phase 4 Hydrea® (hydroxyurea )
5 Rejuvesol® Washed RBC in Sickle Cell Patients Requiring Frequent Transfusions Completed NCT02731157 Phase 4 Rejuvesol
6 Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH) Completed NCT02522104 Phase 4 Siklos
7 Intranasal Fentanyl Versus Intravenous Morphine in the Treatment of Severe Painful Sickle Cell Crises in Children Completed NCT03682211 Phase 4 Fentanyl Citrate;Morphine sulphate
8 Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis Completed NCT01482091 Phase 4 Fentanyl Citrate;Normal Saline
9 Pilot Study for Patients With Poor Response to Deferasirox Completed NCT00749515 Phase 4 Deferoxamine;Deferasirox
10 Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias Recruiting NCT02041299 Phase 4 Deferiprone;Deferoxamine
11 Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE) Recruiting NCT03178643 Phase 4 Proguanil Oral Tablet;Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ);Dihydroartemisinin-Piperaquine (DP)
12 Does IV Acetaminophen Reduce Opioid Requirement in Pediatric Patients With Acute Sickle Cell Crises? Recruiting NCT03541980 Phase 4 Acetaminophen;Normal saline
13 Contraception in Women With Sickle Cell Disease Active, not recruiting NCT02594462 Phase 4 etonogestrel-releasing implant contraceptive
14 Risk Clinical Stratification of Sickle Cell Disease in Nigeria, Assessment of Efficacy/Safety of Hydroxyurea Treatment Active, not recruiting NCT02149537 Phase 4 hydroxyurea
15 Endothelial Monocyte-activating Polypeptide-II in Egyptian Sickle Patients Active, not recruiting NCT03903133 Phase 4 Vitamin E
16 Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias Enrolling by invitation NCT02443545 Phase 4 Deferiprone
17 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Enrolling by invitation NCT03176849 Phase 4
18 Ibuprofen and Opioid (Morphine or Diamorphine) for Acute Pain in Sickle Cell Disease - Sickle With Ibuprofen & Morphine Terminated NCT00880373 Phase 4 Ibuprofen;Placebo;Diamorphine or Morphine
19 Pilot Study on the Effects of Intravenous Ketamine on Acute Pain Crisis in Patients With Sickle Cell Disease Terminated NCT00252122 Phase 4 Ketamine
20 Ketorolac Versus Ibuprofen to Treat Painful Episodes of Sickle Cell Disease Terminated NCT00115336 Phase 4 Intravenous Ketorolac;Ibuprofen
21 Immunogenicity and Safety Study of Pneumococcal 7-Valent Conjugate Vaccine in Sickle Cell Disease Infants. Terminated NCT00368186 Phase 4
22 Assessment of Opioid Analgesia in Sickle Cell Withdrawn NCT00513864 Phase 4 Dextromethorphan;Codeine;Morphine
23 Endothelial Function in Patients With Sickle Cell Anemia Before and After Sildenafil Withdrawn NCT00937144 Phase 4 Viagra (Sildenafil);placebo
24 Transfusion Alternatives Pre-Operatively in Sickle Cell Disease (TAPS) Unknown status NCT00512577 Phase 3
25 Ketamine as an Adjuvant Therapy for Acute Vaso Occlusive Crisis in Pediatric Patients With Sickle Cell Disease Unknown status NCT02801292 Phase 3 Ketamine
26 Vascular Function Intervention Trial in Sickle Cell Disease Unknown status NCT01718054 Phase 2, Phase 3 Chloroquine
27 Prevention of Vaso-occlusive Painful Crisis by Using Omega-3 Fatty Acid Supplements Unknown status NCT02525107 Phase 3
28 Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload Unknown status NCT01511848 Phase 2, Phase 3 DFP (ferriprox) and deferasirox (ICL 670);DFP, DFO
29 Evaluation of the Lung Capillary Blood Volume in Children With Sickle Cell Disease Completed NCT00560261 Phase 3
30 Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC) Completed NCT01737814 Phase 3 Saline;MST-188
31 L-Arginine and Sickle Cell Disease Completed NCT01142219 Phase 3 L-arginine;Placebo
32 N-Acetylcysteine in Patients With Sickle Cell Disease Completed NCT01849016 Phase 3 N-Acetylcysteine;Placebo
33 Hypnosis to Manage Pain and Symptoms in Patients With Sickle Cell Disease Completed NCT00393250 Phase 3
34 A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia Completed NCT01179217 Phase 3 L-glutamine;Placebo
35 Steroid Treatment for Sickle Cell Pain Crisis Completed NCT00263562 Phase 3 Methylprednisolone plus prednisone taper
36 Evaluation of Repeat Administration of Purified Poloxamer 188 Completed NCT02449616 Phase 3 MST-188
37 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease Completed NCT00918580 Phase 3
38 Sulfadoxine- Pyrimethamine Versus Weekly Chloroquine for Malaria Prevention in Children With Sickle Cell Anemia Completed NCT00399074 Phase 3 sulfadoxine pyrimethamine
39 Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease Completed NCT00004408 Phase 3 poloxamer 188
40 Ameliorating Attention Problems in Children With Sickle Cell Disease (SCD) Completed NCT01411280 Phase 3 methylphenidate
41 Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH) Completed NCT00000586 Phase 3 hydroxyurea
42 Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis Completed NCT01197417 Phase 2, Phase 3 Intravenous Magnesium Sulfate;Normal Saline Placebo
43 Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia Completed NCT00006400 Phase 3 Hydroxyurea;Placebo
44 Penicillin Prophylaxis in Sickle Cell Disease (PROPS) Completed NCT00000585 Phase 3 penicillin
45 Effect of Inhaled Nitric Oxide in Acute Chest Syndrome (INOSTA Study) Completed NCT00748423 Phase 2, Phase 3 Nitric Oxide;Placebo
46 Choosing Opioid Management for Pain and Analyzing Acute Chest Syndrome (ACS) Rates Equally Completed NCT01380197 Phase 3 Morphine;Nubain
47 Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial Completed NCT00072761 Phase 3
48 Novel Use Of Hydroxyurea in an African Region With Malaria Completed NCT01976416 Phase 3 Hydroxyurea;Placebo
49 Stroke Prevention in Sickle Cell Anemia (STOP 1) Completed NCT00000592 Phase 3
50 Stroke Prevention in Sickle Cell Anemia (STOP 2) Completed NCT00006182 Phase 3

Search NIH Clinical Center for Sickle Cell Disease

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Sickle Cell Disease

Anatomical Context for Sickle Cell Disease

MalaCards organs/tissues related to Sickle Cell Disease:

42
Bone, Bone Marrow, Testes, Kidney, Endothelial, Brain, Placenta

Publications for Sickle Cell Disease

Articles related to Sickle Cell Disease:

(show top 50) (show all 4139)
# Title Authors Year
1
Management of an adult patient with sickle cell disease and acute chest syndrome by veno-venous extracorporeal membrane oxygenation. ( 30643938 )
2019
2
Low-risk factors for severe bacterial infection and acute chest syndrome in children with sickle cell disease. ( 30740900 )
2019
3
Extracorporeal Life Support for Severe Acute Chest Syndrome in Adult Sickle Cell Disease: A Preliminary Report. ( 30768514 )
2019
4
Candida albicans induced acute chest syndrome in sickle cell disease. ( 30900797 )
2019
5
Asthma in children with sickle cell disease. ( 30883397 )
2019
6
Perioperative Endocarditis Management in a Patient with Homozygous Sickle Cell Disease. ( 30648104 )
2019
7
Incidence of invasive Haemophilus influenzae infections in children with sickle cell disease. ( 30724001 )
2019
8
Health-Related Quality of Life and Personal Life Goals of Adults With Sickle Cell Disease After Hematopoietic Stem Cell Transplantation. ( 29624126 )
2019
9
Ischemia-Reperfusion Injury in Sickle Cell Disease: From Basics to Therapeutics. ( 30904156 )
2019
10
The challenge of differentiating vaso-occlusive crises from osteomyelitis in children with sickle cell disease and bone pain: A 15-year retrospective review. ( 30838073 )
2019
11
Total hip arthroplasty in osteonecrosis secondary to sickle cell disease. ( 29907913 )
2019
12
Purulent Pericarditis in Sickle Cell Disease Due to Streptococcus agalactiae; a Unique Case Report and Literature Review. ( 30879337 )
2019
13
Classic pseudoxanthoma elasticum in a girl with sickle cell disease. ( 30537162 )
2019
14
"A complex interface: Exploring sickle cell disease from a parent's perspective, after moving from Sub-Saharan Africa to North America". ( 30785354 )
2019
15
Cost for sickle cell disease screening using isoelectric focusing with dried blood spot samples and estimation of price thresholds for a point-of-care test in Uganda. ( 30787644 )
2019
16
Social-environmental factors and cognitive and behavioral functioning in pediatric sickle cell disease. ( 30789071 )
2019
17
Parent and Guardian Knowledge of Hematopoietic Cell Transplantation as a Treatment Option for Sickle Cell Disease. ( 30789459 )
2019
18
Ovarian reserve in women with sickle cell disease. ( 30794713 )
2019
19
Sensitization of nociceptors by prostaglandin E2-glycerol contributes to hyperalgesia in mice with sickle cell disease. ( 30796025 )
2019
20
Progressive Decline in Estimated GFR in Patients With Sickle Cell Disease: An Observational Cohort Study. ( 30797615 )
2019
21
Impact of Bariatric Surgery on Outcomes of Patients with Sickle Cell Disease: a Nationwide Inpatient Sample Analysis, 2004-2014. ( 30805858 )
2019
22
Low Incidence of Hospital-Onset Clostridium difficile Infection in Sickle Cell Disease. ( 30811919 )
2019
23
Early Predictors of Renal Dysfunction in Pediatric Patients with Sickle Cell Disease. ( 30814790 )
2019
24
Neurologic Complications of Sickle Cell Disease. ( 30820687 )
2019
25
Sickle cell disease: Hemostatic and inflammatory changes, and their interrelation. ( 30825426 )
2019
26
Developing a problem-solving intervention to improve self-management and transition readiness in adolescents with sickle cell disease. ( 30826724 )
2019
27
Contraceptive Methods and the Impact of Menstruation on Daily Functioning in Women with Sickle Cell Disease. ( 30830232 )
2019
28
Clinical presentation of delayed hemolytic transfusion reactions and hyperhemolysis in sickle cell disease. ( 30837199 )
2019
29
Beta2-Adrenergic Receptor Polymorphisms and Haplotypes Associate With Chronic Pain in Sickle Cell Disease. ( 30837870 )
2019
30
Spontaneous Healing of Avascular Necrosis of the Femoral Head in Sickle Cell Disease. ( 30838665 )
2019
31
Haploidentical bone marrow transplantation improves cerebral hemodynamics in adults with sickle cell disease. ( 30838684 )
2019
32
Challenges in the treatment and prevention of delayed hemolytic transfusion reactions with hyperhemolysis in sickle cell disease patients. ( 30848512 )
2019
33
Elevated urinary 3-indoxyl sulfate in sickle cell disease. ( 30851118 )
2019
34
Transverse colon volvulus in a patient with sickle cell disease. ( 30852505 )
2019
35
An update on arginine in sickle cell disease. ( 30855194 )
2019
36
Red blood cell alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease. ( 30857806 )
2019
37
RETRACTION: Nankanja R, Kiyaga C, Geisberg M, Serrao E, and Balyegyusa S. Implementation of a Sickle Cell Disease Screening Initiative in Uganda with HemoTypeSCTM. Blood. 2018;132(Suppl 1):LBA-3. ( 30858233 )
2019
38
Risk of invasive pneumococcal disease in children with sickle cell disease in the era of conjugate vaccines: a systematic review of the literature. ( 30859558 )
2019
39
HemoTypeSCTM Demonstrates >99% Field Accuracy in a Sickle Cell Disease Screening Initiative in Children of Southeastern Uganda. ( 30859621 )
2019
40
Heart rate variability study in adult Nigerian subjects with sickle cell disease during vaso-occlusive crisis. ( 30860193 )
2019
41
Gastro-splenic fistula, a rare presentation of sickle cell disease patient with splenic abscess: Case report and literature review. ( 30875625 )
2019
42
Improvments in haploidentical transplantation for sickle cell disease and β-thalassaemia. ( 30878318 )
2019
43
Complement activation during intravascular hemolysis: Implication for sickle cell disease and hemolytic transfusion reactions. ( 30879901 )
2019
44
Recommendations for the use of red blood cell exchange in sickle cell disease. ( 30879904 )
2019
45
Effect of chronic opioid therapy on pain and survival in a humanized mouse model of sickle cell disease. ( 30885998 )
2019
46
Epidemiology and Perioperative Complications in Patients With Sickle Cell Disease After Orthopaedic Surgery: 26 Years' Experience at a Major Academic Center. ( 30889039 )
2019
47
Sickle cell disease and readmissions rates after lower extremity arthroplasty: a multistate analysis 2007-2014. ( 30892071 )
2019
48
Pain and sickle cell disease. ( 30893088 )
2019
49
Comparison of Parenteral Opioid Dosing in Adult Sickle Cell Disease Patients With Vaso-occlusive Crisis. ( 30896312 )
2019
50
Neuropathic Pain Screening: Construct Validity in Patients With Sickle Cell Disease. ( 30900520 )
2019

Variations for Sickle Cell Disease

Expression for Sickle Cell Disease

Search GEO for disease gene expression data for Sickle Cell Disease.

Pathways for Sickle Cell Disease

Pathways related to Sickle Cell Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.65 HBB HBD HBG1 HBG2
2 10.7 HBA2 HBB VCAM1
3 10.61 HBA2 HBB SELP VCAM1

GO Terms for Sickle Cell Disease

Cellular components related to Sickle Cell Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.87 EPO HBA2 HBB MIR144 PGF SELP
2 blood microparticle GO:0072562 9.46 HBA2 HBB HBD HBG2
3 hemoglobin complex GO:0005833 9.35 HBA2 HBB HBD HBG1 HBG2
4 endocytic vesicle lumen GO:0071682 9.26 HBA2 HBB
5 haptoglobin-hemoglobin complex GO:0031838 9.02 HBA2 HBB HBD HBG1 HBG2

Biological processes related to Sickle Cell Disease according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 response to hypoxia GO:0001666 9.69 EPO PGF VCAM1
2 response to lipopolysaccharide GO:0032496 9.67 EPO SELP VCAM1
3 cellular oxidant detoxification GO:0098869 9.65 HBA2 HBB HBD HBG1 HBG2
4 blood coagulation GO:0007596 9.62 HBB HBD HBG1 HBG2
5 protein heterooligomerization GO:0051291 9.55 HBA2 HBB HBD HBG1 HBG2
6 leukocyte cell-cell adhesion GO:0007159 9.48 SELP VCAM1
7 cell volume homeostasis GO:0006884 9.46 KCNN4 SLC12A4
8 calcium-mediated signaling using intracellular calcium source GO:0035584 9.43 SELP VCAM1
9 leukocyte tethering or rolling GO:0050901 9.4 SELP VCAM1
10 erythrocyte maturation GO:0043249 9.37 EPO G6PD
11 hydrogen peroxide catabolic process GO:0042744 9.35 HBA2 HBB HBD HBG1 HBG2
12 oxygen transport GO:0015671 9.02 HBA2 HBB HBD HBG1 HBG2

Molecular functions related to Sickle Cell Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heme binding GO:0020037 9.77 HBA2 HBB HBD HBG1 HBG2
2 oxygen binding GO:0019825 9.72 HBA2 HBB HBD HBG1 HBG2
3 peroxidase activity GO:0004601 9.65 HBA2 HBB HBD HBG1 HBG2
4 oxygen carrier activity GO:0005344 9.55 HBA2 HBB HBD HBG1 HBG2
5 hemoglobin alpha binding GO:0031721 9.4 HBB HBD
6 organic acid binding GO:0043177 9.35 HBA2 HBB HBD HBG1 HBG2
7 haptoglobin binding GO:0031720 9.02 HBA2 HBB HBD HBG1 HBG2

Sources for Sickle Cell Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....